Discover 792 paid clinical trials in Round Rock, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 792
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
for
High-Risk Non-Muscle-Invasive Bladder Cancer
Location: Austin TX, San Antonio TX, Houston TX, Arlington TX,
Sponsor: CG Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06567743
Phase 2, Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
for
Superficial Bladder Cancer,
Location: Austin TX, Houston TX, Dallas TX, Little Rock AR,
Sponsor: enGene, Inc.
Sex: All
Age: 18+
Code: NCT04752722
Phase 1, Phase 2, Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
for
Non-Muscle Invasive Bladder Cancer
Location: Austin TX, Houston TX, Dallas TX, New Orleans LA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06319820
Phase 3, Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
for
Bladder (Urothelial, Transitional Cell) Cancer,
Location: Austin TX, Houston TX, Arlington TX, Little Rock AR,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT07480356
Phase 3, Recruiting
Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.
Get alerts for new trials in your area by subscribing now
Optimizing Non-statin Agents for ASCVD
for
ASCVD Management
Location: Austin TX
Sponsor: University of Texas at Austin
Sex: All
Age: 18+
Code: NCT07464574
Recruiting
New
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
for
Healthy Volunteers
Location: Austin TX
Sponsor: Eisai Inc.
Sex: All
Age: 18 - 55
Code: NCT07766369
Phase 1, Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
for
Parkinson Disease
Location: Austin TX, The Villages FL, Orlando FL, Port Orange FL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 30 - 70+
Code: NCT06809400
Phase 1, Recruiting
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
for
Bacterial Conjunctivitis
Location: Austin TX
Sponsor: Senju USA, Inc.
Sex: All
Age: 18+
Code: NCT07565103
Phase 1, Phase 2, Recruiting
Utility of PharmacoGenomics for Reducing Adverse Drug Effects
for
Genetics of Drug Metabolism
Location: Austin TX, Waco TX, League City TX, Lake Charles LA,
Sponsor: Companion Dx Reference Lab, LLC
Sex: All
Age: 18+
Code: NCT02081872
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
for
Systemic Sclerosis
Location: Austin TX, Frisco TX, New Orleans LA, Jackson TN,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07497087
Phase 3, Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
for
Non-small Cell Lung Cancer (NSCLC)
Location: Austin TX, Plano TX, Denton TX, Memphis TN,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07291037
Phase 3, Recruiting
New
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
for
Prostate Cancer
Location: Lakeway TX, San Antonio TX, The Woodlands TX,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06855277
Phase 3, Recruiting
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations